COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions

Adeniji, Opeyemi S.; Giron, Leila B.; Purwar, Mansi; Zilberstein, Netanel F.; Kulkarni, Abhijeet J.; Shaikh, Maliha W.; Balk, Robert A.; Moy, James N.; Forsyth, Christopher B.; Liu, Qin; Dweep, Harsh; Kossenkov, Andrew; Weiner, David B.; Keshavarzian, Ali; Landay, Alan; Abdel-Mohsen, Mohamed

Beyond neutralization, antibodies binding to their Fc receptors elicit several innate immune functions including antibody-dependent complement deposition (ADCD), antibody-dependent cell-mediated phagocytosis (ADCP), and antibody-dependent cell-mediated cytotoxicity (ADCC). These functions are beneficial, as they contribute to pathogen clearance; however, they also can induce inflammation. We tested the possibility that qualitative differences in SARS-CoV-2-specific antibody-mediated innate immune functions contribute to coronavirus disease 2019 (COVID-19) severity. We found that anti-S1 and anti-RBD antibodies from hospitalized COVID-19 patients elicited higher ADCD but lower ADCP compared to antibodies from nonhospitalized COVID-19 patients. Consistently, higher ADCD was associated with higher systemic inflammation, whereas higher ADCP was associated with lower systemic inflammation during COVID-19. Our study points to qualitative, differential features of anti-SARS-CoV-2 specific antibodies as potential contributors to COVID-19 severity. Understanding these qualitative features of natural and vaccine-induced antibodies will be important in achieving optimal efficacy and safety of SARS-CoV-2 vaccines and/or COVID-19 therapeutics.